Role of Rifaximin in Prevention of Spontaneous Bacterial Peritonitis
Current Guideline Recommendations
- The European Association for the Study of the Liver (EASL) guidelines state that rifaximin cannot be recommended as an alternative to norfloxacin for secondary prophylaxis of SBP, despite some promising evidence 1, 2, 3, 4, 5
- Norfloxacin 400 mg orally once daily remains the standard of care for patients who have recovered from an episode of SBP, reducing recurrence from 68% to 20% at one year, as recommended by the EASL guidelines 1, 2, 6
- The EASL guidelines explicitly state that rifaximin has no established role in primary prophylaxis of SBP 1, 2, 3, 4
- Norfloxacin 400 mg daily is recommended for high-risk patients with low ascitic fluid protein and advanced liver failure or renal impairment, according to the EASL guidelines 1, 6
Emerging Research Evidence
- A single-center open-label trial showed rifaximin had lower 6-month SBP recurrence compared with norfloxacin (4% vs. 14%), as reported in the journal Hepatology 6
Important Caveats and Pitfalls
- The most recent high-quality guidelines (2018 EASL, 2021 AASLD, 2021 BSG) do not endorse rifaximin for SBP prophylaxis, despite newer research showing potential benefit, as noted in the Journal of Hepatology and Hepatology 1, 2, 3, 4, 5, 6, 7
- Long-term fluoroquinolone use raises concerns about bacterial resistance and emergence of multidrug-resistant organisms, as reported in Hepatology and Gut 6, 7
- Quinolone prophylaxis is less effective in patients colonized with multidrug-resistant organisms, according to Hepatology 6
- Rifaximin may not prevent all SBP cases, and its efficacy against gram-positive organisms and multidrug-resistant organisms is uncertain, as noted in Hepatology 6
Practical Clinical Approach
- For secondary prophylaxis, the EASL guidelines recommend using norfloxacin 400 mg daily (or ciprofloxacin 500 mg daily if norfloxacin unavailable) 1, 6, 7
- For patients already on rifaximin for hepatic encephalopathy who develop SBP, the EASL guidelines suggest adding norfloxacin for secondary prophylaxis, as there is no evidence to support rifaximin monotherapy for this indication 1, 2, 3, 4, 5
- For primary prophylaxis, the EASL guidelines recommend using norfloxacin in high-risk patients, as rifaximin has no established role 1, 6
Prophylaxis for Spontaneous Bacterial Peritonitis in High-Risk Patients
Introduction to Prophylaxis
- The American Association for the Study of Liver Diseases recommends antibiotic prophylaxis for high-risk cirrhotic patients with ascites based on three specific risk categories: patients with prior SBP, patients with acute gastrointestinal hemorrhage, and selected patients without prior SBP but with high-risk features 8, 9
Secondary Prophylaxis
- Patients who have recovered from a previous episode of SBP should receive continuous antibiotic prophylaxis due to the high risk of recurrence (68% at 1 year without prophylaxis) 8, 10
- The recommended first-line regimen is Norfloxacin 400 mg orally once daily, which reduces recurrence from 68% to 20% 8, 10
Prophylaxis During Acute Gastrointestinal Hemorrhage
- All cirrhotic patients with acute gastrointestinal bleeding should receive antibiotic prophylaxis regardless of ascites presence 9, 11
- The recommended regimen is IV ceftriaxone until bleeding resolves and vasoactive drugs are discontinued 8
Primary Prophylaxis
- Prophylaxis should be reserved for high-risk patients with low ascitic fluid protein (<1.5 g/dL) and at least one of the following criteria: advanced liver failure, impaired renal function, or hyponatremia 8, 12
- The recommended regimen is Norfloxacin 400 mg orally once daily, which reduces SBP occurrence from 61% to 7% 10, 12
Important Considerations
- Prophylaxis should continue indefinitely until liver transplantation or resolution of ascites 10
- Bacterial resistance is an increasing concern with long-term fluoroquinolone use 9, 10
- Consider restricting proton pump inhibitor use in patients on SBP prophylaxis as PPIs may increase SBP risk 10, 12
- The European Association for the Study of the Liver recommends regular monitoring of renal function in patients on prophylactic antibiotics 10